Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | CRHBP | P24387 | 3/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171965 | 0.85 | LMNA (0.55) | LMNAHPGDTDP1GAACRHBP | |
| SCHEMBL171909 | 0.84 | CRHBP (0.58) | LMNATDP1GAACRHBPCRHR2 | |
| SCHEMBL169824 | 0.82 | TDP1 (0.76) | LMNATDP1GAACRHBPCRHR2 | |
| SCHEMBL13607976 | 0.82 | HPGD (0.58) | LMNAHPGDGAACRHBPCRHR2 | |
| SCHEMBL171860 | 0.81 | HPGD (0.59) | LMNAHPGDGAAKMT2AMEN1 | |
| SCHEMBL15074682 | 0.81 | TDP1 (0.54) | LMNATDP1GAACRHBPCRHR2 | |
| SCHEMBL8338584 | 0.80 | HPGD (0.40) | LMNAHPGDTDP1GAACRHBP | |
| SCHEMBL20878928 | 0.80 | LMNA (0.54) | LMNATDP1GAACRHBPCRHR2 | |
| SCHEMBL171986 | 0.79 | LMNA (0.53) | LMNAHPGDTDP1GAACRHBP | |
| SCHEMBL8337202 | 0.79 | HPGD (0.39) | LMNAHPGDTDP1GAACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | LMNA 4752/4885HPGD 3075/4885TDP1 2357/4885 |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | LMNA 4744/4885HPGD 2690/4885TDP1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.